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ABSTRACT
Background Frailty in older age is known to be
associated with cardiovascular disease (CVD) risk.
However, the extent to which frailty is associated with
the CVD risk proﬁle has been little studied. Our aim was
to examine the associations of a range of cardiovascular
risk factors with frailty and to assess whether these are
independent of established CVD.
Methods Cross-sectional study of a socially
representative sample of 1622 surviving men aged
71–92 examined in 2010–2012 across 24 British towns,
from a prospective study initiated in 1978–1980. Frailty
was deﬁned using the Fried phenotype, including weight
loss, grip strength, exhaustion, slowness and low
physical activity.
Results Among 1622 men, 303 (19%) were frail and
876 (54%) were pre-frail. Compared with non-frail,
those with frailty had a higher odds of obesity (OR 2.03,
95% CI 1.38 to 2.99), high waist circumference
(OR 2.30, 95% CI 1.67 to 3.17), low high-density
lipoprotein-cholesterol (HDL-C) (OR 2.28, 95% CI 1.47
to 3.54) and hypertension (OR 1.79, 95% CI 1.27
to 2.54). Prevalence of these factors was also higher in
those with frailty (prevalence in frail vs non-frail groups
was 46% vs 31% for high waist circumference, 20% vs
11% for low HDL and 78% vs 65% for hypertension).
Frail individuals had a worse cardiovascular risk proﬁle
with an increased risk of high heart rate, poor lung
function (forced expiratory volume in 1 s (FEV1)), raised
white cell count (WCC), poor renal function (low
estimated glomerular ﬁltration rate), low alanine
transaminase and low serum sodium. Some risk factors
(HDL-C, hypertension, WCC, FEV1, renal function and
albumin) were also associated with being pre-frail. These
associations remained when men with prevalent CVD
were excluded.
Conclusions Frailty was associated with increased risk
of a range of cardiovascular factors (including obesity,
HDL-C, hypertension, heart rate, lung function, renal
function) in older people; these associations were
independent of established CVD.
INTRODUCTION
The increasing numbers of older people in countries
such as the UK poses a signiﬁcant public health chal-
lenge to improving health and social care outcomes
in older populations.1 A particular concern in older
people is the development of frailty, deﬁned as “a
clinically recognizable state of increased vulnerabil-
ity, resulting from aging-associated decline in reserve
and function across multiple physiologic systems
such that the ability to cope with everyday or acute
stressors is compromised”.2 The reduced resilience
of frail individuals to stressors leads in turn to an
increased vulnerability to adverse outcomes, includ-
ing functional decline, hospitalisation, disability,
long-term care and death.3–5 Frailty therefore repre-
sents one of the greatest challenges for healthcare
professionals in countries with ageing populations
such as the UK.3 A systematic review reported the
prevalence of frailty as between 4% and 59%
(varying due to the varying methods of measuring
frailty) in studies with participants aged ≥65 years.6
Apart from disability and mortality, frailty is also
associated with an increased risk of cardiovascular
disease (CVD). A systematic review showed that
frailty was associated with a twofold to threefold
increase in risk of CVD.7 Frailty is also a strong
predictor of mortality in patients with CVD inde-
pendent of age, disease severity, comorbidity and
disability.7 Previous studies have attempted to
understand the pathophysiology underlying this
collinear relationship between frailty and CVD—
factors that have been found to play a role under-
lying this relationship include inﬂammation, and
other risk factors for CVD and mortality such as
chronic kidney disease and low alanine transamin-
ase (ALT).8–11 However, few population-based
studies have described the cardiovascular risk
proﬁle associated with frail older people.8 9 This is
particularly important since a better understanding
of the cardiovascular risk proﬁle of frail older
adults will enable better clinical management to
reduce the high risk of CVD associated with frailty.
Indeed, the identiﬁcation and management of
frailty is increasingly being recognised as a poten-
tially important aspect of the overall care of older
patients with CVD.7 Furthermore, little is known
about whether an adverse cardiovascular risk
proﬁle is present in frail older adults, even in the
absence of established CVD. Therefore, the aim of
this study was to examine whether frailty was asso-
ciated with a range of cardiovascular risk factors in
a community-dwelling study of older British men
and to investigate whether the associations are
present in those without established CVD.
METHODS
The British Regional Heart Study is a prospective
study of CVD comprising a socially and geographic-
ally representative sample of 7735 men aged
40–59 years from one general practice in each of 24
towns representing all major British regions and
who were initially examined in 1978–1980.12 In
2010–2012, all surviving men (n=3137) now aged
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71–92 years were invited to attend a 30-year re-examination. The
men were requested to fast for a minimum of 6 h and to attend a
measurement session at a speciﬁed time between 08:00 and 18:00.
Participants underwent a physical examination, provided a fasting
blood sample and completed a questionnaire (at the time of exam-
ination or by post if they did not attend) providing information on
their medical history and lifestyle factors. Presence of comorbidity
was based on subjects’ reporting of a doctor diagnosis of the fol-
lowing conditions reported in the questionnaire—history of
angina, heart attack, heart failure, high blood pressure, stroke, per-
ipheral vascular disease (PVD), deep vein thrombosis (DVT), dia-
betes, chronic kidney disease, anaemia, asthma, bronchitis,
arthritis, falls, cataract and depression.
Physical examination of subjects involved anthropometric
(height, weight, waist circumference) and physiological (blood
pressure, lung function) measurements. A 12-lead ECG was
recorded. Height and weight were measured in subjects in light
clothing and without shoes. Height was measured with a
Harpenden stadiometer to the last complete 0.1 cm and weight
with a Tanita MA-418-BC body composition analyser (Tanita,
Tokyo, Japan). Waist circumference (cm) was measured in dupli-
cate with an insertion tape (CMS, London). Waist measurement
was measured from the midpoint between the iliac crest and the
lower ribs measured at the sides. Body mass index (BMI) was
calculated as weight/(height)2 (kg/m2). Blood pressure was mea-
sured using an Omron blood pressure recorder twice in succes-
sion in the right arm, with the subject seated and the arm
supported. The mean of the two blood pressure recordings was
used in the analysis. Physical performance assessments included
a walking test (time taken, in seconds, to walk 3 m at normal
walking pace), and grip strength measured with a Jamar
Hydraulic Hand Dynamometer. Grip strength (in kilograms)
was measured thrice for each hand, and the best of six readings
was used for the analysis.
Blood measurements: Fasting serum samples were measured
for lipids and markers of hepatic and renal function. Total
cholesterol, high-density lipoprotein cholesterol (HDL-C) and
triglycerides were measured with enzymatic colorimetric assays
using methods of Nauck et al and Wahlefeld et al, respect-
ively.13 14 Creatinine,15 alkaline phosphatase16 (ALP) and
hepatic enzymes including ALT17 and γ-glutamyltransferase
(GGT)18 were also measured using enzymatic colorimetric
assays. Albumin,19 calcium,20 magnesium21 and phosphate22
were measured using endpoint colorimetric assays. Sodium was
measured using ion-selective electrode technique.23 Glucose was
measured in a ﬂuoride oxidase plasma sample.24 Impaired
fasting glucose was taken as >6.1 and <7 mmol/L. Estimated
glomerular ﬁltration rate (eGFR), as a measure of renal func-
tion, was estimated from serum creatinine using the modiﬁca-
tion of diet in renal disease equation developed by Levy et al.25
Lung function: Forced expiratory volume in 1 s (FEV1) was
measured as part of lung function tests. Tests were carried out
standing and without nose clips. A Vitalograph Compact II
instrument was used, which was calibrated at least twice daily
using a precision syringe. FEV1 was recorded for the best test,
deﬁned in accordance with the American Thoracic Society
recommendations. Cole has shown that dividing by the height
squared is the most appropriate way of standardising lung func-
tion for stature.26 FEV1 was height standardised to the average
height, 1.71 m, in the study. Thus, height standardised
FEV1=FEV1 × (1.71/height)
2. Low FEV1 was deﬁned as being
in the lowest quartile of FEV1.
Lifestyle factors: Subjects were asked detailed questions about
their smoking and drinking habits. The men were classiﬁed into
groups based on their alcohol intake—none, occasional, light,
moderate and heavy. Heavy drinking was deﬁned as drinking
>6 units (1 UK unit=10 g) of alcohol daily or on most days. In
the questionnaire, subjects were also asked to report their
pattern of physical activity such as walking, cycling and other
sporting activities. Physical activity scores were assigned on the
basis of frequency and type of activity, and the men were
divided into six groups: none, occasional, light, moderate, mod-
erately vigorous and vigorous. Subjects who reported none or
occasional activity were classiﬁed as ‘inactive’.
Deﬁnitions: The International Society for Hypertension
Guidelines (2003) were used to identify patients with hyperten-
sion as with systolic blood pressure ≥160 mm Hg or diastolic
blood pressure ≥90 mm Hg or on antihypertensive treatment.
Low HDL-C was deﬁned as levels <40 mg/dL (<1.04 mmol/L),
and high triglycerides as ≥200 mg/dL (≥2.3 mmol/L).27 Low
sodium was taken as <138 mmol/L. High creatinine, ALP, GGT
and phosphate were taken as the top ﬁfth of the distributions.
Low albumin, ALT, calcium and magnesium were taken as the
bottom ﬁfth of the distribution. High white cell count (WCC)
was taken as the top ﬁfth of the distribution. Anaemia was
deﬁned as haemoglobin levels <13 g/dL.
Assessment of frailty was based on the ‘Fried frailty pheno-
type’4 using both questionnaire and objective data. This
included unintentional weight loss (assessed as ≥5% decrease in
self-reported weight that was reported to be unintentional);
exhaustion (if response to the question ‘Do you feel full of
energy?’ was ‘no’); weakness (assessed as lowest ﬁfth of grip
strength distribution); and slow walking speed (lowest ﬁfth of
walking speed). If walking speed was unavailable, self-report of
slow walking pace (being unable to walk more than a few steps
or <200 yards or difﬁculty walking across a room) or low phys-
ical activity (self-report of being less/much less active than an
average man). Presence of three or more of these components
was deﬁned as frailty, and presence of one or two as pre-frailty.
Statistical analyses
Multivariable logistic regression was used to estimate
age-adjusted odd ratios (ORs) and 95% conﬁdence intervals
(CIs) according to categories of frailty with ‘not frail’ as the refer-
ence group. Box and whisker plots were obtained to present the
distribution of BMI, waist circumference, HDL-C and systolic
blood pressure according to frailty groups. ORs and 95% CI
were calculated for lifestyle factors (smoking, alcohol, obesity,
waist circumference), chronic diseases and vascular risk factors.
RESULTS
A total of 1722 men (55%) attended the examination.
Questionnaires were completed by 2137 men (68% response
rate). Of the 1722 men who attended the examination, 100
men did not have information on measurements for frailty;
therefore, the analysis was restricted to 1622 men.
Among 1622 men aged 71–92 years, 303 men (19%) were
frail and 876 men (54%) were pre-frail. Of the pre-frail group,
57% had one frailty criteria and 43% had two. In the frail
group, 66% had three of the frailty criteria, 30% had four and
4% had ﬁve of the criteria. Table 1 describes the demographic
and lifestyle factors according to frailty. Men in the frail group
were slightly older and less likely to be never smokers compared
with those not frail. Moderate/heavy alcohol consumption was
not associated with frailty.
Table 2 presents the associations between frailty and CVD.
Men with frailty had greater risks of angina, coronary disease,
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stroke, PVD, heart failure, DVT and diabetes. Increased risks of
these conditions were also observed in the pre-frail group.
Figures 1–4 present boxplots with the distribution of key car-
diovascular risk factors (BMI, waist circumference, HDL-C and
systolic blood pressure) according to frailty groups. Median
BMI and waist circumference levels (ﬁgures 1 and 2) were
higher in the frail group compared with the non-frail group (p
values 0.002 and 0.0001, respectively), while HDL-C and sys-
tolic blood pressure (ﬁgures 3 and 4) were lower in those with
frailty (p values 0.02 and <0.001, respectively).
Table 3 shows the associations between cardiovascular risk
factors and frailty, adjusted for age, in all men. Those in the frail
group were twice as likely to be obese and have high waist cir-
cumference; men in the pre-frail group also had an increased
risk of being obese and having high waist circumference.
Prevalence of these factors was also higher in the frail group
(prevalence in frail vs non-frail group was 24% vs 16% for
obesity, 46% vs 31% for high waist circumference, 20% vs 11%
for low HDL-C and 78% vs 65% for hypertension). Those in
the frail group had an increased risk of low HDL-C, hyperten-
sion, high heart rate, high WCC, low FEV1, low haemoglobin,
poor renal function (low eGFR), low albumin, low ALT, high
GGT, high ALP, high phosphate and low sodium. The high risk
of raised GGT in the frail group remained even after adjustment
for waist circumference (OR 1.85; 95% CI 1.25 to 2.74).
Increased risks were also observed in the pre-frail group for
some of these factors, including low HDL-C, hypertension, high
WCC, low FEV1, poor renal function and low albumin.
Table 4 presents the associations between cardiovascular risk
factors and frailty speciﬁcally in 1061 men without established
CVD. Among these men, frailty was associated with an increased
risk of high waist circumference, low HDL-C, high heart rate,
high WCC, low FEV1, low haemoglobin, poor renal function
(low eGFR), low albumin, low ALT, high GGT, high ALP and
Table 2 Cardiovascular disease and related chronic conditions
according to frailty in a population-based study of 1622 older
British men aged 71–92 years
Not frail Pre-frail Frail
Angina
n (%) 45 (10%) 149 (17%) 80 (27%)
OR (95% CI) 1.00 1.75 (1.22 to 2.50) 2.94 (1.64 to 4.45)
Heart attack
n (%) 41 (9%) 123 (14%) 63 (21%)
OR (95% CI) 1.00 1.61 (1.11 to 2.35) 2.64 (1.70 to 4.11)
Stroke
n (%) 23 (5%) 86 (10%) 51 (17%)
OR (95% CI) 1.00 2.00 (1.24 to 3.23) 3.78 (2.22 to 6.45)
Peripheral vascular disease
n (%) 4 (1%) 36 (4%) 22 (7%)
OR (95% CI) 1.00 5.01 (1.77 to 14.20) 10.01 (3.36 to 29.85)
Heart failure
n (%) 1 (0%) 16 (2%) 18 (6%)
OR (95% CI) 1.00 8.56 (1.13 to 64.97) 30.93 (4.05 to 236.43)
Deep vein thrombosis
n (%) 8 (2%) 24 (3%) 18 (6%)
OR (95% CI) 1.00 1.55 (0.69 to 3.50) 3.56 (1.48 to 8.53)
Diabetes
n (%) 60 (14%) 135 (15%) 83 (27%)
OR (95% CI) 1.00 1.24 (0.89 to 1.73) 2.78 (1.89 to 4.09)
All ORs are age-adjusted.
Table 1 Demographic and lifestyle factors according to frailty in a
population-based study of 1622 older British men aged 71–92 years
in 2010–2012
Not frail
(n=443)
Pre-frail
(n=876)
Frail
(n=303)
Age (years)
Mean (SE) 77 (0.21) 79 (0.15) 81 (0.26)
Never smoker
n (%) 189 (43%) 331 (38%) 93 (31%)
OR (95% CI) 1.00 0.85 (0.67 to 1.08) 0.65 (0.47 to 0.89)
Moderate/heavy alcohol consumption
n (%) 20 (5%) 41 (5%) 12 (4%)
OR (95% CI) 1.00 1.16 (0.67 to 2.02) 1.10 (0.52 to 2.33)
Manual social class
n (%) 196 (45%) 385 (45%) 152 (52%)
OR (95% CI) 1.00 1.04 (0.82 to 1.31) 1.44 (1.05 to 1.96)
All ORs are age-adjusted.
Figure 1 Box and whisker plot with the distribution of body mass
index according to frailty groups in 1622 older British men.
Figure 2 Box and whisker plot with the distribution of waist
circumference according to frailty groups in 1622 older British men.
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high phosphate levels. The pre-frail group without previous
CVD was also at an increased risk of having high heart rate, high
WCC, low albumin and high ALP. Tests for interaction showed
that the associations between cardiovascular risk factors and
frailty were not signiﬁcantly different in those with and without
previous CVD (all p values for test for interaction were >0.05).
DISCUSSION
This study in a representative sample of older British men aged
71–92 years shows that frailty in older age is associated with a
range of cardiovascular risk factors (including dyslipidemia,
obesity, poor lung function, poor renal function, raised white
cells, low albumin, low sodium and altered liver function);
several of these cardiovascular factors were also raised or altered
in those who were pre-frail. Moreover, the association of frailty
with cardiovascular risk factors was independent of established
CVD. The results highlight the burden of cardiovascular risk in
the frail as well as the pre-frail older population, and thus the
increased risk of CVD and its complications in frail older
people.
Comparison with other studies
The results of this study present the association of frailty with a
range of vascular factors in older men with and without estab-
lished CVD. The results very clearly demonstrate that frailty is a
condition associated with problems across multiple physiological
systems. Previous studies have shown that frailty is associated
with established cardiovascular risk factors such as blood pres-
sure and HDL-C, and novel risk factors such as inﬂammation.8 9
We also observed such associations of frailty with HDL-C, tri-
glycerides and WCC. Our ﬁndings are also consistent with
recent studies that show that chronic kidney disease and low
ALT are associated with frailty.8–11 Given its association with
frailty and CVD,28 we also investigated anaemia (low haemoglo-
bin level) in relation to frailty. In our study, anaemia was asso-
ciated with frailty, as reported in a previous study in older
women.9 We also observed a greater risk of other factors,
including low albumin and haemoglobin, in those who were
frail. A particularly important aspect of our results was the
ﬁnding that several of these vascular risk factors were also asso-
ciated with those who were pre-frail, that is, those in the early
phases of frailty. Second, these associations with vascular risk
factors were found to be independent of previous CVD.
Strengths and limitations
We present results on a range of vascular factors and their asso-
ciations with frailty in a socially and geographically representa-
tive sample of older British men. We are not aware of previous
studies describing associations between such a range of cardio-
vascular risk factors and frailty in a large population-based
sample of older people. The high follow-up rate (98%) of the
cohort has enabled minimal attrition rates. However, the issue
of survivor bias is inevitable in cohorts of ageing populations,
with frail subjects likely to have died at a higher rate. The very
moderate response rate (55% for the physical examination) is
likely to have selectively excluded subjects who were more frail
and with a worse health proﬁle (as observed in previous exami-
nations).29 These factors are likely to have reduced the preva-
lence of frailty in the study population, but should not have
biased the association between frailty with cardiovascular risk
factors markedly. A limitation of our study is that it comprises
only white European men, and the generalisability of the study
to women and other ethnic groups is limited. Nevertheless, our
results are comparable with other studies comprising women
and non-white ethnic groups.6 9 30 We also acknowledge that
our results are based on cross-sectional analyses—therefore,
while we were able to demonstrate associations between risk
factors and frailty, there is limited evidence for a causal
association.
Implications and conclusions
Our results highlight the adverse cardiovascular risk proﬁle in
frail older people. The presence of associations between a range
of cardiovascular risk factors (not all of which are strongly
age-related) and frailty reﬂects that the relationship between
CVD and frailty is not simply due to ageing. Although the cross-
sectional nature of the analyses limits understanding the direc-
tion of causality in these associations, the results demonstrate
the high risk in older frail populations across markers of cardio-
vascular, renal, liver and haematological function—the range of
markers beyond traditional cardiovascular risk factors (blood
pressure, cholesterol) are indicative of poor general health
across multiple physiological systems in frail older people. This
highlights the high risk of CVD or its complications in frail
Figure 3 Box and whisker plot with the distribution of high-density
lipoprotein (HDL) cholesterol according to frailty groups in 1622 older
British men.
Figure 4 Box and whisker plot with the distribution of systolic blood
pressure according to frailty groups in 1622 older British men.
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older people—this also points to the overwhelming need to
characterise and manage the high cardiovascular risk in frail
older people. Cardiovascular risk factors associated with frailty
and pre-frailty could be used to identify an at-risk group
needing further assessment and possibly intervention aimed at
cardiovascular risk prevention. At the level of the individual
patient, ﬁnding one cardiovascular risk factor should prompt a
review of all others, and the assessment of frailty, so that clinical
care can become anticipatory. The results also demonstrate the
potentially high cardiovascular risk in those who are pre-frail
(or early stages of frailty), and therefore, a greater need to iden-
tify and manage frailty in its early stages in older people.
Table 3 Vascular risk factors according to frailty in a population-based study of 1622 older British men aged 71–92 years
Not frail Pre-frail Frail
Obesity
BMI ≥30 kg/m2 n (%) 71 (16%) 184 (21%) 69 (24%)
OR (95% CI) 1.00 1.56 (1.15 to 2.12) 2.03 (1.38 to 2.99)
High waist circumference (>102 cm) n (%) 139 (31%) 360 (41%) 136 (46%)
OR (95% CI) 1.00 1.69 (1.32 to 2.15) 2.30 (1.67 to 3.17)
Lipid profile
Low HDL (<1.04 mmol/L) n (%) 45 (11%) 123 (15%) 57 (20%)
OR (95% CI) 1.00 1.47 (1.02 to 2.12) 2.28 (1.47 to 3.54)
High LDL (>4 mmol/L) n (%) 48 (11%) 65 (8%) 16 (6%)
OR (95% CI) 1.00 0.66 (0.44 to 0.98) 0.48 (0.26 to 0.89)
High triglycerides (≥2.3 mmol/L) n (%) 30 (7%) 72 (9%) 28 (10%)
OR (95% CI) 1.00 1.31 (0.84 to 2.05) 1.70 (0.97 to 2.97)
Blood pressure
Hypertension n (%) 288 (65%) 652 (74%) 235 (78%)
OR (95% CI) 1.00 1.52 (1.18 to 1.95) 1.79 (1.27 to 2.54)
Heart rate
High heart rate (top quintile ≥77 beats/min) n (%) 67 (15%) 171 (20%) 78 (26%)
OR (95% CI) 1.00 1.34 (0.98 to 1.83) 1.90 (1.30 to 2.78)
Impaired fasting glucose
Glucose >6.1 and <7.0 mmol/L n (%) 58 (15%) 98 (12%) 32 (12%)
OR (95% CI) 1.00 0.80 (0.56 to 1.14) 0.74 (0.46 to 1.20)
WCC
Total WCC (top quintile ≥8.12×109/L) 54 (13%) 181 (22%) 78 (28%)
OR (95% CI) 1.00 1.78 (1.28 to 2.48) 2.39 (1.60 to 3.57)
Lung function
Low FEV1 (bottom quintile ≤1.91 L) n (%) 53 (12%) 155 (19%) 95 (37%)
OR (95% CI) 1.00 1.41 (1.00 to 1.99) 3.05 (2.04 to 4.54)
Low haemoglobin
Haemoglobin (<13 g/dL) n (%) 65 (15%) 173 (20%) 117 (39%)
OR (95% CI) 1.00 1.33 (0.97 to 1.83) 3.13 (2.18 to 4.50)
Renal function
eGFR (<60 mmL/min) n (%) 53 (13%) 192 (23%) 101 (36%)
OR (95% CI) 1.00 1.76 (1.26 to 2.46) 2.80 (1.89 to 4.15)
Albumin
Low albumin (bottom quintile ≤42 g/L) n (%) 38 (9%) 148 (18%) 71 (25%)
OR (95% CI) 1.00 1.95 (1.33 to 2.86) 2.74 (1.76 to 4.27)
Liver enzymes
Low ALT (bottom quintile ≤13I U/L) n (%) 58 (14%) 148 (18%) 81 (29%)
OR (95% CI) 1.00 1.16 (0.83 to 1.62) 1.87 (1.26 to 2.78)
High GGT (top quintile ≥40 IU/L) n (%) 69 (17%) 161 (19%) 75 (27%)
OR (95% CI) 1.00 1.25 (0.92 to 1.72) 2.04 (1.39 to 2.99)
Bone profile
High ALP (top quintile ≥88 IU/L) n (%) 63 (15%) 169 (20%) 77 (27%)
OR (95% CI) 1.00 1.32 (0.96 to 1.82) 1.80 (1.22 to 2.66)
High phosphate (top quintile ≥1.21 mmol/L) n (%) 72 (17%) 173 (21%) 75 (27%)
OR (95% CI) 1.00 1.23 (0.91 to 1.68) 1.71 (1.17 to 2.50)
Sodium
Low sodium (<138 mmol/L) n (%) 30 (7%) 79 (9%) 44 (16%)
OR (95% CI) 1.00 1.24 (0.80 to 1.94) 2.01 (1.20 to 3.36)
All ORs are age-adjusted.
ALP, alkaline phosphatase; BMI, body mass index; eGFR, estimated glomerular filtration rate; GGT, γ-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; WCC, white cell count.
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While there is an increasing recognition of frailty and its con-
sequences in older populations, there are few initiatives imple-
mented with a systematic management of this condition.
Further research is needed to identify the extent to which inter-
ventions reducing cardiovascular risk affect frailty and its
associated outcomes. A joint approach using primary prevention
(early identiﬁcation and management of frailty) and secondary
prevention (management of vascular risk) initiatives is needed to
help reduce the vascular risk and CVD-related consequences
associated with frail older people.
Table 4 Vascular risk factors according to frailty in 1061 older British men aged 71–92 years without established cardiovascular disease
Not frail Pre-frail Frail
Obesity
BMI ≥30 kg/m2 n (%) 56 (16%) 113 (20%) 25 (18%)
OR (95% CI) 1.00 1.41 (0.99 to 2.02) 1.37 (0.79 to 2.34)
High waist circumference (>102 cm) n (%) 107 (31%) 226 (40%) 62 (43%)
OR (95% CI) 1.00 1.62 (1.21 to 2.16) 2.08 (1.37 to 3.18)
Lipid profile
Low HDL (<1.04 mmol/L) n (%) 32 (10%) 69 (13%) 30 (21%)
OR (95% CI) 1.00 1.34 (0.85 to 2.09) 2.60 (1.47 to 4.61)
High LDL (>4 mmol/L) n (%) 44 (14%) 60 (11%) 15 (11%)
OR (95% CI) 1.00 0.78 (0.51 to 1.20) 0.77 (0.40 to 1.48)
High triglycerides (≥2.3 mmol/L) n (%) 22 (7%) 52 (9%) 17 (12%)
OR (95% CI) 1.00 1.52 (0.90 to 2.57) 2.18 (1.09 to 4.36)
Blood pressure
Hypertension n (%) 208 (61%) 380 (66%) 98 (67%)
OR (95% CI) 1.00 1.25 (0.94 to 1.66) 1.17 (0.77 to 1.79)
High heart rate
High heart rate (top quintile ≥77 beats/min) n (%) 54 (16%) 128 (23%) 40 (27%)
OR (95% CI) 1.00 1.55 (1.08 to 2.21) 1.98 (1.22 to 3.21)
Impaired fasting glucose
Glucose (>6.1 and <7.0 mmol/L) n (%) 41 (13%) 68 (13%) 20 (15%)
OR (95% CI) 1.00 0.90 (0.59 to 1.37) 0.91 (0.49 to 1.68)
WCC
Total WCC (top quintile ≥8.12×109/L) 37 (12%) 117 (21%) 32 (23%)
OR (95% CI) 1.00 1.94 (1.29 to 2.90) 1.93 (1.12 to 3.34)
Lung function
Low FEV1 (bottom quintile ≤1.91 L) n (%) 41 (12%) 91 (17%) 42 (24%)
OR (95% CI) 1.00 1.24 (0.82 to 1.86) 2.47 (1.46 to 4.18)
Low haemoglobin
Haemoglobin (<13 g/dl) n (%) 50 (15%) 86 (15%) 46 (31%)
OR (95% CI) 1.00 0.94 (0.64 to 1.38) 2.08 (1.28 to 3.38)
Renal function
eGFR (<60 mmL/min) n (%) 38 (12%) 103 (19%) 45 (32%)
OR (95% CI) 1.00 1.44 (0.95 to 2.17) 2.41 (1.43 to 4.05)
Albumin
Low albumin (bottom quintile ≤42 g/L) n (%) 30 (9%) 110 (20%) 33 (23%)
OR (95% CI) 1.00 2.16 (1.40 to 3.34) 2.26 (1.28 to 3.98)
Liver enzymes
Low ALT (bottom quintile ≤13 IU/L) n (%) 41 (13%) 97 (18%) 45 (32%)
OR (95% CI) 1.00 1.27 (0.85 to 1.90) 2.32 (1.39 to 3.87)
High GGT (top quintile ≥40 IU/L) n (%) 55 (17%) 103 (19%) 39 (28%)
OR (95% CI) 1.00 1.16 (0.81 to 1.68) 2.03 (1.24 to 3.33)
Bone profile
High ALP (top quintile ≥88 IU/L) n (%) 47 (15%) 115 (21%) 38 (27%)
OR (95% CI) 1.00 1.48 (1.02 to 2.16) 1.96 (1.18 to 3.26)
High phosphate (top quintile ≥1.21 mmol/L) n (%) 49 (15%) 101 (18%) 37 (26%)
Sodium
OR (95% CI) 1.00 1.25 (0.86 to 1.83) 2.01 (1.21 to 3.33)
Low sodium (<138 mmol/L) n (%) 25 (8%) 44 (8%) 20 (14%)
OR (95% CI) 1.00 0.89 (0.53 to 1.51) 1.42 (0.73 to 2.77)
All ORs are age-adjusted.
ALP, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in 1 s; GGT,
γ-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; WCC, white cell count.
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Key messages
What is already known on this subject?
▸ Frailty poses an important challenge to health and social
care needs of older populations in countries such as the UK
and is associated with an increased risk of cardiovascular
disease (CVD).
▸ Few population-based studies have described the
cardiovascular risk proﬁle associated with frail older people.
What might this study add?
▸ This study in a community-dwelling sample of 1622 older
men shows that frailty is associated with an adverse
cardiovascular risk proﬁle (including high body mass index
and waist circumference, low high-density
lipoprotein-cholesterol, high blood pressure, high white cell
count, poor lung function, liver function and renal function)
across a range of factors affecting multiple physiological
systems.
▸ Pre-frail groups also demonstrated some increased risk of
these cardiovascular risk factors.
▸ The association of frailty with cardiovascular risk factors was
independent of established CVD.
How might this impact on clinical practice?
▸ Frail and pre-frail older individuals need to be identiﬁed in
clinical practice.
▸ Cardiovascular risk factors associated with frailty and
pre-frailty could be used to identify an at-risk group needing
further assessment and possibly intervention aimed at
cardiovascular risk prevention.
▸ At the level of the individual patient, ﬁnding one
cardiovascular risk factor should prompt a review of all
others, and the assessment of frailty, so that clinical care
can become anticipatory.
▸ Management of cardiovascular risk factors in frail and
pre-frail older people could potentially reduce the burden of
CVD or its complications in frail older people.
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